alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 801.61 Statement of identity. ( a ) The principal display panel of an over-the-counter device in package form shall bear as one of its principal features a statement of the identity of the commodity.
( b ) Such statement of identity shall be in terms of the common name of the device followed by an accurate statement of the principal intended action(s) of the device. Such statement shall be placed in direct conjunction with the most prominent display of the name and shall employ terms descriptive of the principal intended action(s). The indications for use shall be included in the directions for use of the device, as required by section 502(f)(1) of the act and by the regulations in this part.
( c ) The statement of identity shall be presented in bold face type on the principal display panel, shall be in a size reasonably related to the most prominent printed matter on such panel, and shall be in lines generally parallel to the base on which the package rests as it is designed to be displayed.
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1595 Porphyrins test system. ( a ) *Identification.* A porphyrins test system is a device intended to measure porphyrins (compounds formed during the biosynthesis of heme, a constituent of hemoglobin, and related compounds) in urine and feces. Measurements obtained by this device are used in the diagnosis and treatment of lead poisoning, porphyrias (primarily inherited diseases associated with disturbed porphyrin metabolism), and other diseases characterized by alterations in the heme pathway.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2308, Jan. 14, 2000]
§ 582.1778 Sodium phosphate. ( a ) *Product.* Sodium phosphate (mono-, di-, and tribasic).
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
# C_2014175EN.01004601.xml

| 10.6.2014 | EN | Official Journal of the European Union | C 175/46 |
| --- | --- | --- | --- |

10.6.2014

EN

Official Journal of the European Union

C 175/46

---

Action brought on 7 March 2014 — ANKO v Commission

(Case T-154/14)

2014/C 175/63

Language of the case: Greek

Parties

Parties

Applicant: ANKO AE Antiprosopeion, Emporiou kai Viomichanias (Athens, Greece) (represented by: V. Christianos, lawyer)

Applicant:

Defendant: European Commission

Defendant:

Form of order sought

Form of order sought

The applicant claims that the General Court should:

| — | Declare that the entire amount of EUR 185 664,10 which the Commission has already paid to the applicant in respect of the OASIS project and the entire amount of EUR 465 062,84 which the Commission has already paid to the applicant in respect of the PERFORM project constitute eligible costs; |
| --- | --- |

—

Declare that the entire amount of EUR 185 664,10 which the Commission has already paid to the applicant in respect of the OASIS project and the entire amount of EUR 465 062,84 which the Commission has already paid to the applicant in respect of the PERFORM project constitute eligible costs;

| — | Declare that the amount of EUR 1 824,05 which the Commission has not paid in respect of the OASIS project and the amount of EUR 637 117,17 which the Commission has not paid as a portion in respect of the PERFORM project constitute eligible costs and consequently the Commission is under an obligation to pay those sums to ΑΝΚΟ, and |
| --- | --- |

—

Declare that the amount of EUR 1 824,05 which the Commission has not paid in respect of the OASIS project and the amount of EUR 637 117,17 which the Commission has not paid as a portion in respect of the PERFORM project constitute eligible costs and consequently the Commission is under an obligation to pay those sums to ΑΝΚΟ, and

| — | order the Commission to pay the applicant’s legal costs. |
| --- | --- |

—

order the Commission to pay the applicant’s legal costs.

Pleas in law and main arguments

Pleas in law and main arguments

This action concerns the liability of the Commission under the contracts (a) 215 754 and (b) 215 952 for the performance of the (a) OASIS and (b) PERFORM projects respectively, under Article 272 TFEU.

In particular, the applicant maintains that, although it complied with its contractual obligations, the Commission, in breach of the abovementioned contracts, the principle of good faith, the prohibition of abuse of rights and the principle of proportionality, sought the recovery of sums paid to ΑΝΚΟ as not being eligible costs and refused to pay its outstanding portion. For that reason, the applicant maintains, first, that the rejection as constituting ineligible costs of almost all of the Commission’s portion in respect of the OASIS and PERFORM projects is contrary to the Commission’s contractual obligations to ΑΝΚΟ. Second, the applicant maintains that the attempt to recover almost all of those amounts is disproportionate and abusive.

---
Table 9A. Cost Range Stability, weighted by Charges - Values

LOW MEDIUM HIGH

LOW 6,694 437 -

MEDIUM 807 62,966 328

HIGH - 436 7,356

Table 9B. Cost Range Stability, weighted by Charges - Percent

LOW MEDIUM HIGH

LOW 94% 6% 0% 100%

MEDIUM 1% 98% 1% 100%

HIGH 0% 6% 94% 100%

Cost Range w/EP Adjustment

Cost Range w/o EP 

Adjustment

Cost Range w/EP Adjustment Total

Cost Range w/o EP 

Adjustment
Table 9C. Cost Range Stability, weighted by EPs - Values

LOW MEDIUM HIGH

LOW 6,791 409 -

MEDIUM 738 62,975 283

HIGH - 396 7,432

Table 9D. Cost Range Stability, weighted by EPs - Percent

LOW MEDIUM HIGH

LOW 94% 6% 0% 100%

MEDIUM 1% 98% 0% 100%

HIGH 0% 5% 95% 100%

Total

Cost Range w/o EP 

Adjustment

Cost Range w/EP Adjustment

Cost Range w/o EP 

Adjustment

Cost Range w/EP Adjustment
# C_2015221EN.01001901.xml

| 6.7.2015 | EN | Official Journal of the European Union | C 221/19 |
| --- | --- | --- | --- |

6.7.2015

EN

Official Journal of the European Union

C 221/19

---

Order of the General Court of 13 May 2015 — Klar and Fernandez Fernandez v Commission

(Case T-665/14 P) (1)

1

((Appeal - Civil Service - Officials - Staff Committee of the Commission - Revocation by the Luxembourg local section of one of its members appointed to the central staff committee - Decision refusing to recognise the lawfulness of the revocation decision - Action at first instance dismissed as manifestly inadmissible - Non respect of the pre-litigation procedure - Measure adversely affecting a person - Appeal in part manifestly inadmissible and in part manifestly unfounded))

(2015/C 221/26)

Language of the case: French

Parties

Parties

Appellants: Robert Klar (Grevenmacher, Luxembourg) and Francisco Fernandez Fernandez (Steinsel, Luxembourg) (represented by: A. Salerno, lawyer)

Appellants:

Other party to the proceedings: European Commission (represented by: C. Ehrbar and J. Currall, acting as Agents)

Other party to the proceedings:

Re:

Re:

Appeal against the order of the Civil Service Tribunal of the European Union (Third Chamber) of 16 July 2014 in Klar and Fernandez Fernandez v Commission (F-114/13, ECR-SC, EU:F:2014:192), seeking to have that order set aside.

Klar and Fernandez Fernandez

Commission

Operative part of the order

Operative part of the order

| 1. | The appeal is dismissed; |
| --- | --- |

1.

The appeal is dismissed;

| 2. | Mr Robert Klar and Mr Francisco Fernandez Fernandez are ordered to bear their own costs and those incurred by the European Commission in the context of the present proceedings. |
| --- | --- |

2.

Mr Robert Klar and Mr Francisco Fernandez Fernandez are ordered to bear their own costs and those incurred by the European Commission in the context of the present proceedings.

---

(1)  OJ C 380, 27.10.2014.

1

---
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.1150 Dihydroxyacetone. ( a ) *Identity.* ( 1 ) The color additive dihydroxyacetone is 1,3-dihydroxy-2-propanone.
( 2 ) Color additive mixtures for drug use made with dihydroxyacetone may contain only those diluents that are listed in this subpart as safe and suitable in color additive mixtures for coloring externally applied drugs.
( b ) *Specifications.* Dihydroxyacetone shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by good manufacturing practice: Volatile matter (at 34.6 °C. for 3 hours at a pressure of not more than 30 mm. mercury), not more than 0.5 percent. Residue on ignition, not more than 0.4 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Iron (as Fe), not more than 25 parts per million. 1,3-dihydroxy-2-propanone, not less than 98 percent.
( c ) *Uses and restrictions.* Dihydroxyacetone may be safely used in amounts consistent with good manufacturing practice in externally applied drugs intended solely or in part to impart a color to the human body. Authorization for this use shall not be construed as waiving any of the requirements of section 505 of the act with respect to the drug in which it is used.
( d ) *Labeling requirements.* The label of the color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( e ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health and therefore batches thereof are exempt from the certification requirements of section 721(c) of the act.
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.7300 Fibrin monomer paracoagulation test. ( a ) *Identification.* A fibrin monomer paracoagulation test is a device used to detect fibrin monomer in the diagnosis of disseminated intravascular coagulation (nonlocalized clotting within a blood vessel) or in the differential diagnosis between disseminated intravascular coagulation and primary fibrinolysis (dissolution of the fibrin in a blood clot).
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9. The special control for this device is FDA's “In Vitro Diagnostic Fibrin Monomer Paracoagulation Test.” See § 864.1(d) for information on obtaining this document.
[45 FR 60614, Sept. 12, 1980, as amended at 52 FR 17733, May 11, 1987; 65 FR 17144, Mar. 31, 2000, 84 FR 71799, Dec. 30, 2019]
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3390 *Neisseria* spp. direct serological test reagents. ( a ) *Identification. Neisseria* spp. direct serological test reagents are devices that consist of antigens and antisera used in serological tests to identify *Neisseria* spp. from cultured isolates. Additionally, some of these reagents consist of *Neisseria* spp. antisera conjugated with a fluorescent dye (immunofluorescent reagents) which may be used to detect the presence of *Neisseria* spp. directly from clinical specimens. The identification aids in the diagnosis of disease caused by bacteria belonging to the genus *Neisseria,* such as epidemic cerebrospinal meningitis, meningococcal disease, and gonorrhea, and also provides epidemiological information on diseases caused by these microorganisms. The device does not include products for the detection of gonorrhea in humans by indirect methods, such as detection of antibodies or of oxidase produced by gonococcal organisms.
( b ) *Classification.* Class II (performance standards).
EXHIBIT 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

      In connection  with the Quarterly  Report of Central  Wireless,  Inc. (the
"Company") on Form 10-QSB for the quarter ended March 31, 2003 as filed with the
Securities and Exchange  Commission on the date hereof (the  "Report"),  each of
the  undersigned,  in the capacities and on the dates  indicated  below,  hereby
certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that to his knowledge:

          1. The Report fully complies with the requirements of Section 13(a) or
     15(d) of the Securities Exchange Act of 1934; and

          2. The  information  contained in the Report fairly  presents,  in all
     material respects,  the financial condition and results of operation of the
     Company.

Date: March 19, 2004                    By: /s/ Kenneth W. Brand
                                           -------------------------------------
                                           Name:  Kenneth W. Brand
                                           Title: Chief Executive Officer and
                                                  acting Principal Accounting
                                                  Officer

A signed  original of this written  statement  required by Section 906, or other
document  authentications,  acknowledging,  or otherwise  adopting the signature
that  appears  in typed  form  within the  electornic  version  of this  written
statement  required by Section 906, has been provided to Central Wireless,  Inc.
and will be retained by Central  Wireless,  Inc. and furnished to the Securities
and Exchange Commission or its staff upon request.
**Exhibit 31.2**

 

**CERTIFICATION**

 

I, Richard J. Baum, certifythat:

 

1. I have reviewed thisquarterly report on Form 10-Q, as amended, of Ebix, Inc.;

 

2. Based on my knowledge, thisreport does not contain any untrue statement of a material fact or omit to statea material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading withrespect to the period covered by this report;

 

3. Based on my knowledge, thefinancial statements, and other financial information included in this report,fairly present in all material respects the financial condition, results ofoperations and cash flows of the registrant as of, and for, the periodspresented in this report;

 

4. The registrant’s othercertifying officer and I are responsible for establishing and maintainingdisclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)and 15d-15(e)) for the registrant and have:

 

(a) Designed such disclosurecontrols and procedures, or caused such disclosure controls and procedures tobe designed under our supervision, to ensure that material information relatingto the registrant, including its consolidated subsidiaries, is made known to usby others within those entities, particularly during the period in which thisreport is being prepared;

 

(b) Evaluated the effectivenessof the registrant’s disclosure controls and procedures and presented in thisreport our conclusions about the effectiveness of the disclosure controls andprocedures, as of the end of the period covered by this report based on suchevaluation; and

 

(c) Disclosed in this reportany change in the registrant’s internal control over financial reporting thatoccurred during the registrant’s most recent fiscal quarter (the registrant’sfourth fiscal quarter in the case of an annual report) that has materiallyaffected, or is reasonably likely to materially affect, the registrant’sinternal control over financial reporting; and

 

5. The registrant’s othercertifying officer and I have disclosed, based on our most recent evaluation ofinternal control over financial reporting, to the registrant’s auditors and theaudit committee of the registrant’s board of directors (or persons performingthe equivalent functions):

 

(a) All significant deficienciesand material weaknesses in the design or operation of internal control overfinancial reporting which are reasonably likely to adversely affect theregistrant’s ability to record, process, summarize and report financialinformation; and

 

(b) Any fraud, whether or notmaterial, that involves management or other employees who have a significantrole in the registrant’s internal control over financial reporting.

 

 
| Date:  | May 20, 2005            | /s/ Richard J. Baum |   |
|--------|-------------------------|---------------------|--------|
|   | Richard J. Baum         |
|   | Chief Financial Officer |

 

----
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5220 Cohn fraction II immunological test system. ( a ) *Identification.* A Cohn fraction II immunological test system is a device that consists of the reagents that contain or are used to measure that fraction of plasma containing protein gamma globulins, predominantly of the IgG class. The device may be used as a coprecipitant in radioimmunoassay methods, as raw material for the purification of IgG subclasses, and to reduce nonspecific adsorption of plasma proteins in immunoassay techniques. Measurement of these proteins aids in the diagnosis of any disease concerned with abnormal levels of IgG gamma globulins such as agammaglobulinemia or multiple myeloma.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 59 FR 63007, Dec. 7, 1994; 66 FR 38793, July 25, 2001]
SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   ----------

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                                   ----------

        Date of Report (Date of earliest event reported): April 24, 2003

                           OMEGA FINANCIAL CORPORATION
                           ---------------------------
             (Exact name of Registrant as specified in its charter)

 Pennsylvania                       0-13599                    25-1420888
 ------------                       -------                    ----------
(State or other             (Commission File Number)        (I.R.S. Employee
jurisdiction of                                           Identification Number)
incorporation)

                                366 Walker Drive
                             State College, PA 16801
                             -----------------------
          (Address of principal executive offices, including zip code)

       Registrant's telephone number, including area code: (814) 231-7680


<PAGE>

                                    Form 8-K

Item 7. Financial Statements and Exhibits

      (a) Not applicable.
      (b) Not applicable.
      (c) Exhibits.

            99.1  Press Release, dated April 24, 2003

Item 9. Regulation FD Disclosure (Information provided under Item 12 - Results
of Operations and Financial Condition.)

      On April 24, 2003, Omega Financial Corporation issued a press release
reporting financial results for the first quarter of fiscal year 2003. A copy of
the Press Release is being furnished as Exhibit 99.1 to this report and is
incorporated into this report by reference.

      Item 12 of Form 8-K, "Results of Operations and Financial Condition,"
requires the Company to furnish the Press Release to the Securities and Exchange
Commission. In accordance with interim guidance issued by the Securities and
Exchange Commission in Release No. 33-8216, Omega Financial Corporation is
furnishing the Press Release required by Item 12 under Item 9 of this report.

      The information being furnished under Item 9 of this report shall not be
considered "filed" for purposes of the Securities Exchange Act of 1934, as
amended.


<PAGE>

Signatures:

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date: April 24, 2003

                                      Omega Financial Corporation

                                      By: /s/  Daniel L. Warfel
                                          ----------------------------------
                                          Name: Daniel L. Warfel
                                          Title: EVP and Chief Financial Officer
# C_2016027EN.01004602.xml

| 25.1.2016 | EN | Official Journal of the European Union | C 27/46 |
| --- | --- | --- | --- |

25.1.2016

EN

Official Journal of the European Union

C 27/46

---

Judgment of the General Court of 26 November 2015 — Établissement Amra v OHIM (KJ KANGOO JUMPS XR)

(Case T-390/14) (1)

1

((Community trade mark - Application for Community trade mark KJ Kangoo Jumps XR - Absolute ground for refusal - Devoid of any distinctive character - Article 7(1)(b) of Regulation No 207/2009))

(2016/C 027/57)

Language of the case: English

Parties

Parties

Applicant: Établissement Amra (Vaduz, Liechtenstein) (represented by: S. Rizzo, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: J. Crespo Carrillo, acting as Agent)

Defendant:

Re:

Re:

Action brought against the decision of the Second Board of Appeal of OHIM of 10 March 2014 (Case R 1511/2013-2), concerning an application for registration of the ‘3D position mark’ KJ Kangoo Jumps XR as a Community trade mark.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Établissement Amra to pay the costs. |
| --- | --- |

2.

Orders Établissement Amra to pay the costs.

---

(1)  OJ C 315, 15.9.2014.

1

---
132 STAT. 4430 PUBLIC LAW 115–313—DEC. 13, 2018 

LEGISLATIVE HISTORY—S. 3414: 

CONGRESSIONAL RECORD, Vol. 164 (2018): 

Nov. 15, considered and passed Senate. 

Nov. 29, considered and passed House. 

Æ 

Public Law 115–313 

115th Congress 

An Act 

To designate the facility of the United States Postal Service located at 20 Ferry 

Road in Saunderstown, Rhode Island, as the ‘‘Captain Matthew J. August Post 

Office’’. 

Be it enacted by the Senate and House of Representatives of 

the United States of America in Congress assembled, 

SECTION 1. CAPTAIN MATTHEW J. AUGUST POST OFFICE. 

(a) DESIGNATION.—The facility of the United States Postal 

Service located at 20 Ferry Road in Saunderstown, Rhode Island, 

shall be known and designated as the ‘‘Captain Matthew J. August 

Post Office’’. 

(b) REFERENCES.—Any reference in a law, map, regulation, 

document, paper, or other record of the United States to the facility 

referred to in subsection (a) shall be deemed to be a reference 

to the ‘‘Captain Matthew J. August Post Office’’. 

Approved December 13, 2018. 

Dec. 13, 2018 

[S. 3414] 


dkrause on DSKBC28HB2PROD with PUBLAWS